DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development

Department of Immunology and Oncology, Centro Nacional de Biotecnología, Universidad Autónoma, Campus de Cantoblanco, E-28049 Madrid, Spain.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 08/1999; 96(14):7992-7. DOI: 10.1073/pnas.96.14.7992
Source: PubMed


The DIO-1 (death inducer-obliterator-1) gene, identified by differential display PCR in pre-B WOL-1 cells undergoing apoptosis, encodes a putative transcription factor whose protein has two Zn finger motifs, nuclear localization signals, and transcriptional activation domains, expressed in the limb interdigitating webs during development. When overexpressed, DIO-1 translocates to the nucleus and activates apoptosis in vitro. Nuclear translocation as well as induction of apoptosis are lost after deletion of the nuclear localization sequences. DIO-1 apoptotic induction is prevented by caspase inhibitors and Bcl-2 overexpression. The in vivo role of DIO-1 was studied by misexpressing DIO-1 during chicken limb development. The most frequently observed phenotype was an arrest in limb outgrowth, an effect that correlates with the inhibition of mesodermal and ectodermal genes involved in this process. Our data demonstrate the ability of DIO-1 to trigger apoptotic processes in vitro and suggest a role for this gene in cell death during development.

Download full-text


Available from: Juan P Albar, Oct 05, 2015
10 Reads
  • Source
    • "Active caspase-8 initiates a cascade of caspases which mediate apoptosis [25]. Another example is a large increase in the expression of DIO-1 (death inducer-obliterator-1) that translocates to the nucleus and activates apoptosis in cell culture [26]. KIAA1199 knockdown also led to up-regulation of A-kinase anchor protein 8 (AKAP95) that is a potential carrier protein for active caspase 3, carrying it from the cytoplasm into the nuclei in apoptotic cells and is involved in the process of apoptotic nuclear morphological change [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: KIAA1199 is a recently identified novel gene that is up-regulated in human cancer with poor survival. Our proteomic study on signaling polarity in chemotactic cells revealed KIAA1199 as a novel protein target that may be involved in cellular chemotaxis and motility. In the present study, we examined the functional significance of KIAA1199 expression in breast cancer growth, motility and invasiveness. We validated the previous microarray observation by tissue microarray immunohistochemistry using a TMA slide containing 12 breast tumor tissue cores and 12 corresponding normal tissues. We performed the shRNA-mediated knockdown of KIAA1199 in MDA-MB-231 and HS578T cells to study the role of this protein in cell proliferation, migration and apoptosis in vitro. We studied the effects of KIAA1199 knockdown in vivo in two groups of mice (n = 5). We carried out the SILAC LC-MS/MS based proteomic studies on the involvement of KIAA1199 in breast cancer. KIAA1199 mRNA and protein was significantly overexpressed in breast tumor specimens and cell lines as compared with non-neoplastic breast tissues from large-scale microarray and studies of breast cancer cell lines and tumors. To gain deeper insights into the novel role of KIAA1199 in breast cancer, we modulated KIAA1199 expression using shRNA-mediated knockdown in two breast cancer cell lines (MDA-MB-231 and HS578T), expressing higher levels of KIAA1199. The KIAA1199 knockdown cells showed reduced motility and cell proliferation in vitro. Moreover, when the knockdown cells were injected into the mammary fat pads of female athymic nude mice, there was a significant decrease in tumor incidence and growth. In addition, quantitative proteomic analysis revealed that knockdown of KIAA1199 in breast cancer (MDA-MB-231) cells affected a broad range of cellular functions including apoptosis, metabolism and cell motility. Our findings indicate that KIAA1199 may play an important role in breast tumor growth and invasiveness, and that it may represent a novel target for biomarker development and a novel therapeutic target for breast cancer.
    BMC Cancer 03/2014; 14(1):194. DOI:10.1186/1471-2407-14-194 · 3.36 Impact Factor
  • Source
    • "DIO-1 was identified by differential display PCR in pre-B WOL-1 cells undergoing apoptosis by interleukin-7 (IL-7) starvation. The DIO-1 gene is located at 20q13.33 in Homo sapiens, and its amino acid sequence exhibits predicted transcriptional activation domains consisting of a canonical bipartite nuclear localization signal (NLS) in the N-terminal region, two Zn-finger motifs in the central region, and a C-terminal lysine-rich sequence49. The expression level of DIO-1 is low in WOL-1 cells in the logarithmic growth period. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gambogic acid (GA) is the main active ingredient of gamboge, a brownish to orange dry resin secreted from Garcinia hanburyi, a plant that is widely distributed in nature. Recent in vitro and in vivo studies have demonstrated that GA exerts potent antitumor effects against solid tumors of various derivations, and its antitumor mechanisms have been thoroughly investigated. On the other hand, normal cells remain relatively resistant to GA, indicating a therapeutic window. GA is currently in clinical trials in China. Over the last decade, our laboratory demonstrates that GA exhibits potent anticancer activities against hematological malignancies. This review focuses on the new mechanisms through which GA inhibits proliferation and induces apoptosis in malignant hematological cells. These include the regulation of expression and intracellular positioning of nucleoporin and nucleophosmin; downregulation of steroid receptor coactivator-3 (SRC-3) and its downstream proteins; upregulation of death inducer-obliterator (DIO-1); downregulation of HERG potassium channel; as well as induction of reactive oxygen species (ROS) accumulation.
    Acta Pharmacologica Sinica 12/2012; 34(2). DOI:10.1038/aps.2012.163 · 2.91 Impact Factor
  • Source
    • "Certain of the downregulated genes were associated with apoptosis, including the death inducer-obliterator 1 (DIDO1) , fibroblast growth factor receptor 3 (FGFR3) , and CD24 (Table 2) . DIDO1 is upregulated at an early stage in apoptotic cell death (Garcia-Domingo et al., 1999) . FGFR3 knockdown in human bladder carcinoma cells induces cellcycle progression arrest and influences tumorigenesis (Qing et al., 2009) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Even though exposure to benzene has been linked to a variety of cancers including leukemia, the detailed molecular mechanisms relevant to benzene-induced carcinogenesis remain to be clearly elucidated. In this study, we evaluated the effects of benzene on differential gene expression in a leukemia cell line. The K562 leukemia cell line used in this study was cultured for 3 h with 10 mM benzene and RNA was extracted. To analyze the gene expression profiles, a 41,000 human whole genome chip was employed for cDNA microarray analysis. We initially identified 6,562 genes whose expression was altered by benzene treatment. Among these, 3,395 genes were upregulated and 3,167 genes were downregulated by more than 2-fold, respectively. The results of functional classification showed that the identified genes were involved in biological pathways including transcription, cell proliferation, the cell cycle, and apoptosis. These gene expression profiles should provide us with further insights into the molecular mechanisms underlying benzene-induced carcinogenesis, including leukemia.
    Toxicological Research 03/2011; 27(1):43-48. DOI:10.5487/TR.2011.27.1.043
Show more